Biomarin Pharmaceutical Forecast, price target & analysts
Biomarin Pharmaceutical Target price 2025 - Analyst rating & recommendation
Biomarin Pharmaceutical Classifications & Recommendation:
Biomarin Pharmaceutical Price Target
| Target Price | $97.32 |
| Price | $69.44 |
| Potential |
40.15%
register free of charge
|
| Number of Estimates | 25 |
|
25 Analysts have issued a price target Biomarin Pharmaceutical 2026 .
The average Biomarin Pharmaceutical target price is $97.32.
This is
40.15%
register free of charge
$126.00
81.45%
register free of charge
$65.00
6.39%
register free of charge
|
|
| A rating was issued by 30 analysts: 24 Analysts recommend Biomarin Pharmaceutical to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2026 of
40.15%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.84 | 3.14 |
| 17.35% | 10.58% | |
| EBITDA Margin | 22.06% | 28.29% |
| 78.58% | 28.26% | |
| Net Margin | 14.85% | 19.27% |
| 114.00% | 29.78% |
25 Analysts have issued a sales forecast Biomarin Pharmaceutical 2025 . The average Biomarin Pharmaceutical sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2025. The average Biomarin Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2025. The average Biomarin Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.21 | 3.17 |
| 151.14% | 43.44% | |
| P/E | 21.90 | |
| EV/Sales | 4.06 |
18 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Biomarin Pharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Biomarin Pharmaceutical...
Current Biomarin Pharmaceutical Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 20 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
